Alluvi, previously BI 4744, offers a notable development in weight control therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates impressive results in research studies, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/